Age Range
18+
Trial Purpose
Inhloso yalolu cwaningo ukuhlola ukuphepha nokubekezelelana kanye nokuqinisekisa umthamo we-nemtabrutinib ngokuhlanganiswa ne-venetoclax kubahlanganyeli abane-R/R CLL/SLL. Imibono yocwaningo eyinhloko ukuthi inhlanganisela ye-nemtabrutinib kanye ne-venetoclax iphakeme kune-VR ngokuphathelene nokusinda kwe-progression-free (PFS) ngo-2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) indlela yokuhlola njengoba ihlolwe yi- blinded independent central review (BICR).
NATIONAL TRIAL REFERENCE NUMBER
I-NCT05947851
EU CT Number
2022-501560-17-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
About The Study
Zonke iziguli ezibhalisela ukuhlola zizothola imithi ngenkathi usocwaningweni.
Engxenyeni yoku-1, zonke iziguli zizothola i-nemtabrutinib ne-venetoclax
Engxenyeni yesi-2, ama-50% eziguli azothola i-nemtabrutinib ne-venetoclax
Engxenyeni yesi-2, ama-50% eziguli azothola i-venetoclax ne-rituximab
Trial Phase
Trial start and end dates
- Actual study start date Agasti 8, 2023
- Estimated primary completion date Juni 27, 2033
- Estimated study completion date Juni 27, 2033